This paper is only available as a PDF. To read, Please Download here.
Abstract
As a result of the development of novel chemotherapeutic drugs and targeted biologic
agents, the treatment of colon cancer has changed significantly over the past 10 years.
Today, we have more active agents to use in colon cancer than ever before. The better
understanding underlying the pathogenesis of this disease at the molecular level has
allowed us to take advantage of 2 key pathways, the angiogenic and epidermal growth
factor (EGF) signaling pathways. The combination of traditional chemotherapy drugs
with agents that inhibit these pathways has led to a significant improvement in survival.
At present, patients with metastatic colon cancer routinely achieve a median survival
time > 2 years. The numerous agents available have made the choice of initial treatment
more difficult for a newly diagnosed patient. Herein, we review the 2 main molecular
targets of biologic therapy in colon cancer and examine the clinical evidence for
regimens that inhibit angiogenesis and EGF receptor alone or in combination for newly
diagnosed metastatic colorectal cancer.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2007.CA Cancer J Clin. 2007; 57: 43-66
- Targeted therapy in colorectal cancer.Clin Adv Hematol Oncol. 2006; 4: 124-132
- Avastin [package insert]. Genentech Pharmaceuticals, South San Francisco, CA2007
- Tumor angiogenesis: therapeutic implications.N Engl J Med. 1971; 285: 1182-1186
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.Nature. 1993; 362: 841-844
- Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer.Br J Cancer. 1998; 78: 1379-1384
- VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.Neoplasia. 2001; 3: 420-427
- Association of VEGF genotype with mRNA level in colorectal adenocarcinomas.Biochem Biophys Res Commun. 2004; 325: 144-150
- Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors.J Clin Oncol. 2006; 24 (Abstract 13061).: 606s
- Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (ILV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors.J Clin Oncol. 2006; 24 (Abstract 13161).: 614s
- The new paradigm in the treatment of colorectal cancer: are we hitting the right target?.Expert Opin Investig Drugs. 2007; 16: 311-324
- Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.Clin Cancer Res. 2004; 10: 6487-6501
- The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.Clin Cancer Res. 2005; 11: 4521-4532
- Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.Endocr Relat Cancer. 2003; 10: 1-21
- ErbB family targeting.Curr Opin Investig Drugs. 2003; 4: 1451-1454
- Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.Cancer Res. 2006; 66: 404-411
- Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.Ann Surg. 2006; 243 (discussion 843-4.): 833-842
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med. 2004; 350: 2335-2342
- Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: updated efficacy data.J Clin Oncol. 2007; 25 (Abstract 4027).: 170s
- Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI.J Clin Oncol. 2007; 25 (Abstract 4068).: 180s
- Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second-and third-line settings.Semin Oncol. 2006; 33: S15-S18
- Bevacizumab in combination with chemotherapy: firstline treatment of patients with metastatic colorectal cancer.Semin Oncol. 2006; 33: S8-14
- Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trail in first-line metastatic colorectal cancer.J Clin Oncol. 2007; 25 (Abstract 4028).: 170s
- Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.J Clin Oncol. 2007; 25 (Abstract 4064).: 179s
- A randomized, double-blind, placebocontrolled, phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1).J Clin Oncol. 2005; 23 (Abstract 3).: 2s
- Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial.J Clin Oncol. 2007; 25 (Abstract 4000).: 164s
- Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study.J Clin Oncol. 2007; 25 (Abstract 4035).: 172s
- Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results.J Clin Oncol. 2006; 24 (Abstract 3509).: 148s
- Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.J Clin Oncol. 2007; 25: 4557-4561
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med. 2004; 351: 337-345
- Phase II trial of FOLFOX6, bevacizumab and cetuximab in patients with colorectal cancer.J Clin Oncol. 2007; 25 (Abstract 4075).: 182s
- Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer.Ann Oncol. 2007; 18: 1185-1189
- An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC).Ann Oncol. 2007; 18 (Abstract 0-0033).: vii21
Tol J, Koopman M, Rodenburg CJ, et al. Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOXB) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis. Presented at: the 14th European Cancer Conference; September 23-27, 2007; Barcelona, Spain.
Article info
Publication history
Accepted:
December 6,
2007
Received in revised form:
November 26,
2007
Received:
October 10,
2007
Footnotes
This article includes discussion of investigational and/or unlabeled uses of drugs, including the use of aflibercept, vatalanib, erlotinib, and cetuximab in metastatic colorectal cancer.
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
